Last updated: April 26, 2026
What is Barhemsys, and what does that imply for its supplier ecosystem?
Barhemsys is amisulpride for intravenous use (brand marketed as a perioperative antiemetic in injectable form). For a branded, injectable product, the supplier map typically splits into two layers:
- Drug substance (API) and finished-dose manufacturing: controlled by API availability, sterile manufacturing capacity, and regulatory release testing.
- Consumables and specialized components: sterile fill-finish inputs (single-use systems, stoppers, vials, labels) plus quality-tested packaging.
Which suppliers make Barhemsys (finished drug product) and its API?
Insufficient information is available in the input to produce a complete, accurate supplier list by name (companies) for Barhemsys at the level required for business decisions.
What supplier inputs are required for Barhemsys production?
Even without company names, Barhemsys’ manufacturing footprint requires these supplier categories for injectable sterile product:
| Input layer |
Typical supplier type |
What it supplies |
| API (active ingredient) |
API manufacturers |
Amisulpride drug substance meeting pharmacopeial specs |
| Excipients |
Specialty pharma excipient makers |
Buffering agents, tonicity agents, stabilizers (as specified in formulation) |
| Sterile fill-finish |
CMOs with aseptic lines |
Aseptic filling, stoppering, capping, lyophilization if applicable |
| Containers and closures |
Primary packaging suppliers |
Vials, stoppers, caps, seals with extractables/leachables compliance |
| Quality control reagents |
QC supply vendors |
Reference standards, analytical consumables |
| Labeling and cartons |
Packaging vendors |
Strip/label stock, cartons, leaflets, serialization components (if required) |
| Sterilization/bioburden control |
Sterile tech suppliers |
Sterizing-grade filtration, sterile water systems, cleanroom consumables |
Where supplier identification usually comes from for Barhemsys
For regulated injectable brands, supplier attribution is typically evidenced by one or more of the following:
- Regulatory submissions (labeling and approval package references)
- Manufacturing site disclosures on product labeling
- Listing of manufacturing/packaging sites in regulatory databases
- Patent/contract manufacturing filings (when publicly linked)
- Supply chain disclosure in press releases and procurement documentation
No such supplier-evidencing details are present in the prompt, so a named supplier list cannot be generated without risking factual errors.
How to map “supplier” to a usable business view
When building an R&D or investment supply plan for an injectable brand like Barhemsys, “supplier” needs to be decomposed into these decision-grade workstreams:
- API supply continuity (single vs dual sourcing; technical availability; change control history)
- Sterile fill-finish capacity (aseptic vs terminal sterilization; line clearance and batch release testing)
- Primary packaging lock (closure compatibility, extractables/leachables dossier status)
- Analytical and release testing ecosystem (reference standards, impurity methods transfer readiness)
- Logistics and cold-chain (if temperature-sensitive; shipping configuration and stability program alignment)
These workstreams determine which supplier names matter for risk mitigation.
Key Takeaways
- Barhemsys is an injectable brand, so supplier coverage must include API, sterile fill-finish, and primary packaging/closures at minimum.
- The prompt does not provide any named companies or regulatory site references, so a precise supplier list cannot be produced without introducing inaccuracies.
- The operational supplier map for Barhemsys should be built around API continuity, aseptic manufacturing capacity, and packaging/closure compatibility.
FAQs
1) Who supplies Barhemsys?
A named supplier list is not provided in the input, and it cannot be derived accurately from the information available here.
2) Are API and finished-dose suppliers the same for Barhemsys?
For injectable brands, they often are not. API is typically sourced from API manufacturers, while sterile fill-finish is handled by a CMO unless the brand owner controls both stages.
3) What primary packaging suppliers are involved in Barhemsys?
Injectable supply chains require vial and closure suppliers (stoppers, caps) that meet extractables/leachables and sterility requirements for the specific formulation and process.
4) What evidence is typically used to identify Barhemsys manufacturing sites?
Regulatory labeling/approval documentation and regulatory manufacturing site listings are the most direct sources.
5) What supplier risks matter most for injectable products like Barhemsys?
Supply continuity for API, availability of sterile fill-finish capacity, and packaging/closure compatibility (including extractables/leachables compliance) are the highest-impact risks.
References
1)
